CRISPR Therapeutics’ (CRSP) “Buy” Rating Reiterated at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $84.00 price objective on the stock. A number of other brokerages have also recently issued reports on CRSP. Morgan Stanley […]
Needham & Company LLC reaffirmed their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $84.00 price objective on the stock. A number of other brokerages have also recently issued reports on CRSP. Morgan Stanley […]
